Results 191 to 200 of about 48,766 (300)

A case report on atypical chromosomal variations in Turner syndrome. [PDF]

open access: yesMol Cytogenet
Aliazami F   +5 more
europepmc   +1 more source

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

open access: yesAndrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz   +12 more
wiley   +1 more source

The Incremental Yield of CMA Over Karyotype in Fetal Growth Restriction-A Systematic Review and Meta-Analysis. [PDF]

open access: yesPrenat Diagn
Sapantzoglou I   +8 more
europepmc   +1 more source

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

open access: yesBritish Journal of Haematology, EarlyView.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen   +11 more
wiley   +1 more source

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

open access: yesCancer Science, EarlyView.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito   +17 more
wiley   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

open access: yesCancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou   +15 more
wiley   +1 more source

Protocol for deriving proliferating primary fibroblast cultures from Malabar red snapper larvae for cytogenetic analysis. [PDF]

open access: yesSTAR Protoc
Purushothaman K   +11 more
europepmc   +1 more source

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway

open access: yesCancer Science, EarlyView.
This study provides the first comprehensive characterization of the functional impact, and mechanistic role of FAT4 in MM. Our findings highlight the tumor‐suppressive role of FAT4 in MM and uncover a novel mechanism by which FAT4 regulates the Hippo/YAP pathway.
Lina Zhang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy